LTR Pharma Limited (ASX:LTP) Signs Collaborative Agreement for OROFLOW® Development
LTR Pharma (ASX:LTP) collaborates with SDS to develop OROFLOW®, a novel intranasal spray for Oesophageal Motility Disorders.
LTR Pharma Limited
LTR Pharma (ASX:LTP) collaborates with SDS to develop OROFLOW®, a novel intranasal spray for Oesophageal Motility Disorders.
LTR Pharma (ASX:LTP) achieves FDA approval path for SPONTAN and launches Roxus to accelerate US market entry.